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IMPORTING A HEADACHE FOR  
WHICH THERE’S NO MEDICINE:  
WHY DRUG REIMPORTATION  
SHOULD AND WILL FAIL 
Devin Taylor*
INTRODUCTION 
On Canusa Avenue houses on one side of the street are in 
Canada while houses right across the street are in Beebe Plain, 
Vermont.1 When the Canadian residents of Canusa Avenue need 
medication for high cholesterol they can purchase a ninety-day 
supply of twenty milligram Lipitor for one hundred seventy 
dollars.2 On the other side of the street, the very same supply 
costs the Vermont residents approximately three hundred thirty 
dollars in the United States.3
This astonishing price difference is illustrative of the realities 
of the modern marketplace: United States citizens are paying 
between 35% and 55% more for brand name prescription drugs 
than people around the world.4 Canada’s Patented Medicines 
* Brooklyn Law School Class of 2008; B.A. Wake Forest University, 
2002. The author wishes to thank his parents Brian and Jackie Taylor and 
brother, Kyle Taylor for their love and support. He would also like to thank 
Doris Lane, Dr. Paul Orser and his friends for their encouragement and 
guidance over many years. Many thanks to the members of the Brooklyn 
Journal of Law and Policy, particularly Leon Yel, Heather Maly, Stephen 
Blank and Lee Jacobs. 
1 Vermont v. Leavitt, 405 F. Supp. 2d 466, 469 (D. Vt. 2005). 
2 Id. 
3 Id. 
4 Melicia Seay, Drug Importation: Health Policy Tracking Service Issue 
DEVIN.DOC 7/1/2007 11:05 PM 
1422 JOURNAL OF LAW AND POLICY 
                                                          
Price Review Board (“PMPRB”) estimated that Americans pay 
67% more for brand name drugs than Canadians.5 Additionally, 
one estimate suggests that U.S. consumers would have saved 
$59.7 billion had they purchased all their brand name 
prescription drugs at Canadian prices in 2004.6 In perspective, 
that amount exceeds the combined gross national products of 
Kuwait, Iceland and Jamaica.7
The extreme price difference has created problems for 
Americans who often ration drugs instead of taking the 
prescribed dosage or choose between purchasing the drugs they 
need and other necessities.8 Understandably, many Americans 
are upset about having to make these difficult choices, while 
Canadian neighbors can purchase the very same drugs at a 
fraction of the price. 
This reality is especially frustrating considering many of 
these drugs were manufactured in the United States and 
produced by U.S. pharmaceutical companies.9 Logically, this 
outrage has turned to ingenuity as many Americans are buying 
drugs from Canada to the dismay of the Food and Drug 
Administration (“FDA”).10 In 2003 “nearly five million 
shipments, comprising about 12 million prescription drug 
products with a value of approximately $700 million entered the 
U.S. from Canada.”11
The federal government needs to address soaring drug prices 
in order to make prescription drugs affordable for the entire 
Brief, Health Policy Tracking Service (Thomson West), July 10, 2006 at 1, 
available at http://www.netscan.com/EG-NSCNFS-B02/HPTSFILES% 
5CISSUEBRIEFS%5CDrug1460.pdf. 
5 Id. 
6 Vermont, 405 F. Supp. at 469. 
7 Id. 
8 See Montgomery County v. Leavitt, 445 F. Supp. 2d 505, 507 (D. 
Md. 2006). 
9 Seay, supra note 4, at 2. 
10 Id. 
11 HHS Task Force on Drug Importation, Report on Prescription Drug 
Importation, ix (Dec. 2004), http://www.hhs.gov/importtaskforce/ 
Report1220.pdf. 
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citizenry. One potential course of action that has been the 
subject of debate is drug reimportation. Drug reimportation 
“involves people in this country buying American-made 
prescription drugs from countries to which U.S. pharmaceutical 
companies export their products, either by traveling there to buy 
drugs or purchasing them through the mail.”12 However, drug 
reimportation from foreign countries is not the appropriate 
solution to escalating drug prices. 
This note will explore and identify the reasons that 
meaningful drug reimportation legislation will not pass, as well 
as the reasons that a reimportation plan would be unsuccessful. 
Part I of this note will explore current federal statutes, including 
state response to the perceived failings of the federal government 
and litigation involving drug reimportation and the authority of 
the Secretary of Health and Human Services (“HHS”) under the 
Federal Food Drug and Cosmetics Act (“FDCA”). Part II deals 
with the reasons for the drastic price differences between the 
United States and Canada. Part III explores the FDA’s 
regulatory regime and examines the dangers of bringing drugs 
from foreign sources into the United States, as well as the steps 
the FDA has taken to enforce the law. Part IV discusses State 
experiences with drug reimportation and the shortcomings that 
have been identified. Part V investigates the strength of the 
pharmaceutical lobby, its resources and manpower as well as its 
ability to get results that favor drug companies. Finally, Part VI 
will explore the current state of the law and potential changes in 
the future. 
I.  DRUG REIMPORTATION AND THE LAW 
The federal government, through a series of statutes has 
created a system that makes it impossible for prescription drugs 
to be imported into the United States without the consent of the 
12 Colleen Newvine, Conference explores pros and cons of drug 
reimportation, University of Michigan News Service (2003), 
http://www.umich.edu/~urecord/0304/Nov03_03/07.shtml. 
DEVIN.DOC 7/1/2007 11:05 PM 
1424 JOURNAL OF LAW AND POLICY 
                                                          
HHS Secretary.13 The past three HHS Secretaries have refused 
to allow drug reimportation14 and courts have unequivocally 
upheld the ability of the HHS Secretary to deny importation.15 
In response to rising drug costs and the federal government’s 
current unwillingness to act, some state governments have 
initiated importation programs for their citizens, creating tension 
with federal agencies.16 Ultimately this tension has surfaced in 
litigation where courts have uniformly endorsed the authority of 
the federal government in this matter.17
A.  Federal Law 
The current law, under the FDCA, allows only drug 
manufacturers to import prescription drugs that were originally 
manufactured in the United States back into this country.18 
There are two exceptions to this rule:19 (1) the HHS Secretary 
has the ability to authorize importation for emergency use;20 and 
(2) importation may be allowed under the Medicare 
Modernization Act’s (“MMA”) importation provision.21 The 
MMA has a provision authorizing the HHS Secretary to 
“promulgate regulations” allowing importation of prescription 
drugs into the United States from Canada.22 Furthermore, the 
MMA states that the HHS Secretary “may grant to individuals, 
by regulation or on a case-by-case basis, a waiver of the 
prohibition of importation of a prescription drug or device or 
class of prescription drugs or devices, under such conditions as 
13 See discussion infra Part I.A. 
14 Id. 
15 See infra Part I.C. 
16 See infra Part I.B. 
17 See infra Part I.C. 
18 21 U.S.C. § 381(d)(1) (2006). 
19 21 U.S.C. § 381(d)(2); Medicare Prescription Drug, Improvement and 
Modernization Act of 2003, Pub. L. No. 108-173, § 804(b) (2003). 
20 21 U.S.C. § 381(d)(2). 
21 Pub. L. No. 108-73, § 804(b). 
22 Id. 
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the Secretary determines to be appropriate.”23 For either of 
these exceptions, the Secretary must certify to Congress that 
implementation “will pose no additional risk to the public’s 
health and safety; and result in significant reduction in the cost 
of covered products to the American consumer.”24
The MMA replaced the Medicine Equity and Drug Safety 
Act of 200025 (“MEDS Act”), which likewise allowed the HHS 
Secretary “to pass regulations allowing commercial importation 
of prescription drugs.”26 The MEDS Act also conditioned 
importation on a certification to Congress by the HHS Secretary. 
Neither former HHS Secretary Donna Shalala, under President 
Bill Clinton, nor former Secretary Tommy Thompson, under 
President George W. Bush, approved certification for any 
prescription drug.27 Likewise, current HHS Secretary, Michael 
Leavitt, has refused to issue a certification under the MMA.28
Moreover, the FDCA establishes a “closed” system where 
“the FDA regulates the manufacture, marketing and labeling of 
drugs sold in the United States.”29 Any drugs not manufactured 
according to the FDA’s current “good manufacturing practice” 
(“cGMP”) per the FDCA are not allowed into interstate 
commerce.30 Unless a drug meets all U.S. packing, labeling and 
dosage requirements it will not be approved, even if it is a 
foreign version of an FDA approved drug.31 Thus the FDCA is 
designed to keep pharmaceutical drugs within the closed system, 
monitored by the FDA. 
23 Pub. L. No. 108-73, § 804(j)(2)(A). 
24 Pub. L. No. 108-73, § 804(l)(1). 
25 Medicine Equity and Drug Safety Act of 2000, Pub. L. No. 106-387 
(2000). 
26 Vermont v. Leavitt, 405 F. Supp. 2d 466, 474 (D. Vt. 2005). 
27 Id. 
28 Id. 
29 Id. at 473. 
30 21 U.S.C. § 351(a) (2006). 
31 See 21 U.S.C. § 331(a),(d) (2006). 
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B. State Response 
Due to the federal government’s perceived inability to make 
progress in reducing the price of prescription drugs, many state 
governments have decided to enter the Canadian market.32 Some 
have even created websites linking to Canadian pharmacies so 
that state residents can fill prescriptions at Canadian prices.33 In 
February 2004, Minnesota became the first to create such a 
website, and by the end of the same year, eight other states had 
followed.34 Eleven states35 and the District of Columbia now 
have such websites.36 Illinois Governor Rod Blagojevich has 
been, perhaps, the most aggressive participant in the drug 
reimportation debate. In 2004, Blagojevich and Wisconsin 
Governor Jim Doyle started the I-SaveRx program37 which 
permits Illinois and Wisconsin residents access to less expensive 
prescription drugs from Canada, Ireland and the United 
Kingdom via a website and telephone number.38 The program 
utilizes CanaRx, “a pharmacy benefits manager that operates a 
network of online pharmacies,”39 to offer drug information from 
nearly sixty pharmacies in Canada, Ireland and the United 
Kingdom for approximately one hundred twenty commonly 
prescribed drugs.40
Prior to the unveiling of I-SaveRx, Blagojevich 
32 Seay, supra note 4, at 5. 
33 Id. 
34 Id. 
35 Minnesota, Wisconsin, New Hampshire, North Dakota, Rhode Island, 
Illinois, Washington, Missouri, Vermont, Nevada and Kansas offer access to 
imported drugs to their residents via the internet. Melicia Seay, Drug 
Importation: Health Policy Tracking Service Issue Brief, Health Policy 
Tracking Service (Thomson West), Jan. 8, 2007 at 6, available at 
http://www.netscan.com/EG-NSCNFS-B02/HPTSFILES%5CISSUEBRIEFS 
%5CDrug1680.pdf. 
36 Id. 
37 http://www.i-saverx.net/ 
38 Seay, supra note 4, at 5-6. 
39 Id. at 6. 
40 Id. 
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commissioned a study on the potential cost savings associated 
with drug reimportation.41 The results of the study indicated that 
the state could develop a system with “safety checks equal to or 
greater than Illinois’ current pharmaceutical system and achieve 
savings of up to $90.7 million.”42 In fact Blagojevich said “we 
suspected that the Canadian procedures for distributing, labeling 
and handling prescription drugs were safe, but we didn’t expect 
them in some cases to be even safer than the procedures we use 
here in the United States.”43 Additionally Blagojevich charged, 
“it’s time the FDA stops protecting the big drug companies, it’s 
time they start helping people.”44
However, a major problem with these state initiatives is that 
they may be unreliable. For example, during the first two weeks 
of February 2005, only a few months after the launch of I-
SaveRx, the FDA blocked over 25% of the shipments from 
Canadian pharmacies to U.S. consumers purchased thru the I-
SaveRx program.45 The FDA maintains that current law, under 
the FDCA, allows only drug manufacturers to import 
prescription drugs that were originally made in the United 
States.46 According to the FDA, “the law was designed to 
facilitate a closed drug distribution system to ensure that the 
domestic drug supply is safe and effective.”47 Although the 
FDA has not yet initiated a lawsuit against any of the states, the 
FDA has seized shipments from Canada intended for U.S. 
consumers.48 Thus this conflict may create disincentives to 
41 Press Release, Office of the Governor, Blagojevich releases much-
anticipated report on feasibility and savings of prescription drug importation 
(Oct. 27, 2003) (on file with author), http://www.illinois.gov/ 
PressReleases/ShowPressRelease.cfm?SubjectID=3&RecNum=2346. 
42 Id. 
43 Id. 
44 Id. 
45 Seay, supra note 4, at 6. 
46 Id. at 1. 
47 Id. 
48 Id. at 6 (citing that “during the first two weeks of February 2005, the 
FDA blocked more than 25 percent of prescription drug shipments purchased 
by U.S. residents from Canada through the I-SaveRx program.”). 
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utilize the programs. 
Additionally, the state solution is inadequate because 
consumers in thirty-nine states do not have access to such 
programs.49 Many state governors oppose programs such as I-
SaveRx because they violate federal law, but others are 
distressed by the fact that initiating such programs could make 
the state liable for its failings.50 After vetoing a series of bills 
approved by the California state legislature that would have 
created a web site linking California residents to Canadian 
pharmacies, California Governor Arnold Schwarzenegger51 said: 
“Importing drugs from Canada or assisting residents in their 
efforts to do so would violate federal law and could expose the 
state to civil, criminal and tort liability.”52 Therefore, while 
state action has been influential in bringing the concerns 
surrounding drug reimportation to the foreground, it has not 
yielded permanent solutions that can be enjoyed by the entire 
citizenry. 
C.  Judicial Review 
By including provisions for the possibility of drug 
reimportation, the MMA may have provided hope for those in 
favor of reimportation. However, in practice these provisions 
have achieved little since courts have given great deference to 
the findings of the HHS Secretary and have been unwilling to 
subject the Secretary’s findings or the FDA’s enforcement to 
49 Id. at 7. 
50 Seay, supra note 4, at 8. 
51 In 2006, Governor Schwarzenegger changed his position, writing a 
letter asking Congress to relax federal barriers to buying drugs from foreign 
countries. Critics have speculated that Schwarzenegger’s new position is 
political posturing and not his true feelings on the issue. Melicia Seay, Drug 
Importation: Health Policy Tracking Service Issue Brief, Health Policy 
Tracking Service (Thomson West), Oct. 2, 2006 at 14, available at 
http://www.netscan.com/EG-NSCNFS-B02/HPTSFILES%5CISSUE 
BRIEFS%5CDrug1558.pdf. 
52 Id. at 8. 
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judicial review.53 In United States v. Rx Depot, Inc.54 the 
United States District Court of Oklahoma supported the FDA’s 
finding that Rx Depot was illegally importing drugs from 
Canada. Meanwhile, in both Vermont v. Leavitt55 and 
Montgomery County v. Leavitt,56 courts upheld the discretion of 
the HHS Secretary in granting or denying states’ waivers 
allowing drug importation.57
In Rx Depot, the United States District Court of Oklahoma 
issued an injunction against Rx Depot, Inc., an organization 
operating to assist U.S. citizens in purchasing drugs from 
Canada.58 This organization had nearly 85 storefronts 
throughout the United States and served around 800 customers 
per day.59 Customers were able to mail or fax their medical 
history, a prescription and other documents to one of the 
storefronts, and an employee would then send the information 
and the customer’s credit card information to a Canadian 
pharmacy.60 A Canadian doctor would then write a new 
prescription which would be filled in Canada and shipped to the 
U.S. customer.61 The owners of Rx Depot would receive 
between a ten and twelve percent commission on each order.62 
The court affirmed the FDA’s finding that this organization 
violated U.S. law each time it imported prescription drugs from 
Canada.63 Moreover the court supported the FDA’s use of 
53 Andrews v. United States Dep’t of Health and Human Services, 2005 
U.S. Dist. LEXIS 5710, at 9 (D.D.C. 2005); Vermont v. Leavitt, 405 F. 
Supp. 2d 466, 475 (D. Vt. 2005); Montgomery County v. Leavitt, 445 F. 
Supp. 2d 505, 513 (D. Md. 2006). 
54 290 F. Supp. 2d 1238, 1252 (N.D. Okla. 2003). 
55 Vermont v. Leavitt, 405 F. Supp. 2d 466 (D. Vt. 2005). 
56 Montgomery County v. Leavitt, 445 F. Supp. 2d 505 (D. Md. 2006). 
57 405 F. Supp. 2d at 474; 445 F. Supp. 2d at 512. 
58 Rx Depot, 290 F. Supp. 2d 1238, 1240. 
59 Id. at 1240. 
60 Id. at 1240-41. 
61 Id. at 1241. 
62 United States v. Rx Depot, 290 F. Supp. 2d 1238, 1241 (N.D. Okla. 
2003). 
63 Id. at 1245. 
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discretion in selectively enforcing illegal drug reimportation due 
to the Agency’s limited resources.64
Additionally, courts have denied states the opportunity to 
legally import drugs into the U.S.65 In Vermont v. Leavitt, the 
state of Vermont brought suit against HHS Secretary Michael 
Leavitt because Leavitt denied Vermont’s petition to initiate a 
state run importation program in which prescriptions would be 
forwarded to a “Canadian firm where the prescription would be 
reviewed by a physician familiar with the member’s medical 
history and re-written as a Canadian prescription, which would 
be forwarded to a licensed Canadian pharmacy to be filled and 
sent by mail to the member in the United States.”66 The impetus 
for the lawsuit was Vermont’s concerns about the number of 
citizens already importing drugs from nearby Canada and the 
safety of individual citizens bringing home drugs from across the 
border.67 The state believed that it would be better equipped to 
deal with the safety issues than individual citizens and 
complained that the state does not “have the opportunity to 
intervene to minimize the risks associated with prescription 
medications obtained outside the U.S.”68
The Vermont court agreed with the court in Rx Depot69 that 
this is an issue for Congress, saying “to the precise question at 
issue,”70 the court “must give effect to the unambiguously 
expressed intent of Congress.”71 In interpreting the intent of 
Congress, the court did not equivocate, saying “[g]iven the 
legislative history, it is difficult to escape the conclusion that 
Congress expected the importation provisions of the MMA 
64 Id. at 1249 (finding that this ruling was in response to RxDepot’s 
claim that the FDA was being “unconstitutionally selective” in its 
enforcement of the FDCA). 
65 Vermont v. Leavitt, 405 F. Supp. 2d at 470. 
66 Id. at 471. 
67 Id. 
68 Id. 
69 United States v. Rx Depot, 290 F. Supp. 2d 1238, 1245 (N.D. Okla. 
2003). 
70 Vermont v. Leavitt, 405 F. Supp. 2d at 470. 
71 Id. 
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would never be implemented.”72 In finding against Vermont, the 
court concluded that Vermont’s proposed program was illegal 
and that based on the MEDS Act and the MMA it is clear that 
certification of drug reimportation depends solely on the 
discretion of the HHS Secretary.73
In 2006, in Montgomery County v. Leavitt, Montgomery 
County, Maryland sought a waiver from the FDA, under the 
MMA, allowing its residents to import drugs from Canada.74 
Unlike the claim from Vermont,75 Montgomery County claimed 
it was entitled to a waiver simply because its residents were 
paying too much money for prescription drugs.76 In a letter to 
HHS Secretary Mike Leavitt, County Executive Douglas Duncan 
claimed that residents of the county were forced to “‘choose 
between their health and putting food on the table’”77 and that it 
is “fundamentally unfair that people living in Canada pay a 
fraction of what Americans pay for the same prescription.”78
The FDA denied the waiver application on the basis that it 
would be virtually impossible for a foreign wholesaler to meet 
all the requirements of the FDCA.79 Moreover, the Agency felt 
that it would be deceptive and dangerous to allow the 
importation of drugs that American consumers believed to have 
originated in Canada, when actually many of these drugs 
“originate from other countries such as India and Costa Rica.”80
In addition, Montgomery County claimed that since the FDA 
had often failed to enforce provisions of the FDCA the result is 
a de facto waiver for drug reimportation.81 Once again, the 
court disagreed and found that the FDA has “absolute 
72 Id. at 478. 
73 Id. at 478-79. 
74 Id. at 507. 
75 Vermont v. Leavitt, 405 F. Supp. 2d at 470. 
76 Montgomery County v. Leavitt, 445 F. Supp. 2d 505, 507 (D. Md. 
2006). 
77 Id. 
78 Id. 
79 Id. at 508. 
80 See id. at 507. 
81 Id. at 512. 
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discretion” whether or not to prosecute or enforce a particular 
provision.82 Furthermore, the court affirmed the HHS 
Secretary’s sole discretion as to whether to grant waivers and 
stated that based on the language of the legislation there is no 
issue for judicial review.83 The Montgomery County court, like 
the court in Vermont v. Leavitt, found that changes to drug 
reimportation must be made by Congress since the HHS 
Secretary’s actions were in accordance with all relevant 
legislation.84 Significantly, these cases solidified the role of the 
FDA and the HHS Secretary as the gatekeepers to drug 
reimportation. 
II.  WHY IS THERE A PRICE DIFFERENTIAL? 
There are several reasons why brand name prescription 
drugs are more expensive in the United States, though experts 
disagree on which reasons wield the most influence.85 Drug 
companies often cite “research and development” of new drugs 
as the most important reason for soaring drug prices.86 In 2001, 
brand name drug companies spent over $30 billion on research 
and development.87 Although developing even one new drug 
takes an average of eleven years and costs over $800 million, an 
independent study showed that 65% of the new drugs approved 
by the FDA from 1989 to 2000 “contained active ingredients 
already present in products available on the market,”88 which 
indicates “that the industry has not introduced many new and 
innovative drugs to the market.”89
82 Montgomery County v. Leavitt, 445 F. Supp. 2d 505, 512 (D. Md. 
2006). 
83 Id. at 514. 
84 Id. at 516. 
85 Farin Khosravi, Price Discrimination in the United States: Why Are 
Pharmaceuticals Cheaper in Canada and Are Americans Seizing 
Opportunities Across the Border?, 9 L. & BUS. REV. AM. 427, 429 (2003). 
86 Id. 
87 Id. 
88 Id. 
89 Id. 
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Advertising poses another significant expense for 
pharmaceutical companies.90 The average pharmaceutical 
manufacturer spends 27% of their total revenues on “marketing, 
advertising and administration.”91 Most companies commit a 
greater number of employees to marketing than to research 
activities.92 For example, the top nine brand name drug 
manufacturers employed on average 81% more people in their 
marketing departments than in research and development.93 
Moreover from 1995 to 2000, “research personnel in these nine 
companies declined by 2 percent, while marketing staff 
increased by 59 percent.”94
Executives in pharmaceutical companies are also often paid 
significantly more than their counterparts in other industries.95 
In 2001 the average annual income of the highest paid executive 
at the nine major pharmaceutical manufacturers was nearly $21 
million, not including unexercised stock options which averaged 
$48 million in 2001 alone.96
Further, pharmaceutical manufacturers are required to give a 
24% discount to the four largest federal customers97 and drug 
manufacturers are similarly mandated to give discounts to 
Medicaid per the Omnibus Reconciliation Act of 1990 
(“OBRA”).98 These discounts shift the cost to other consumers 
via increased prices as the manufacturers look to recover lost 
profits from their discounted sales.99
American consumers face the additional obstacle created by 
price regulation policies of foreign countries, including 
Canada.100 In order to control drug prices some countries will 
90 Khosravi, supra note 85, at 431. 
91 Id. at 430. 
92 Id. at 430-31. 
93 Id. at 431. 
94 Id. 
95 Khosravi, supra note 85, at 431. 
96 Id. 
97 Id. 
98 Id. 
99 Id. 
100 Khosravi, supra note 85, at 432. 
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regulate the cost of drugs.101 Often those countries will negotiate 
prices directly with the drug manufacturers that are significantly 
less expensive than what the American consumer is paying.102 
Particularly frustrating about this policy to many Americans is 
that they feel as though they are subsidizing the cost of 
prescription drugs of other countries.103
In fact, price controls are just one of the techniques the 
Canadian government has used to regulate the price of drugs 
within their borders.104 In the 1960’s Canada had some of the 
highest drug prices of any country.105 In response to soaring 
prices the Canadian government created a regulatory scheme that 
allowed generic drugs into the marketplace prior to the 
expiration of the drug patent.106 Amid criticism that this scheme 
did not allow drug companies to recover their costs for research 
and development, the Canadian legislature, in 1987, “passed Bill 
C-22, which gave the Canadian patent-holder an exclusive right 
to market the drug for the first seven years of the patent 
term.”107 Then in 1993, Canada implemented Bill C-91 which 
extended the patent term from seven to twenty years.108
Bill C-22 created the Patented Medicine Prices Review 
Board (PMPRB) “to enforce price controls on patented 
medicines.”109 The PMPRB is an independent arm of the 
government that has the ability to “investigate and regulate 
excessive pricing” of patented pharmaceutical drugs.110 
According to Bob Nakagawa, Assistant Deputy Minister, 
Pharmaceutical Services for the British Columbia Ministry of 
Health, the prices of all drugs must fit within a specific range 
101 Id. 
102 Id. 
103 See discussion supra Part I.C. 
104 Khosravi, supra note 85, at 433. 
105 Id. 
106 Id. 
107 Id. 
108 Id. 
109 Khosravi, supra note 85, at 433. 
110 Id. 
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determined by the PMPRB.111 Moreover, the PMRRB monitors 
drug prices and has the power to lower prices and levy fines to 
those charging excessive rates.112 A drug in a “new class” 
cannot be sold at a price that exceeds the median price for the 
same drug in seven countries.113 For drugs that fall into an 
existing class, a manufacturer cannot set the price higher than 
what is currently being charged in Canada.114 Prices can be 
raised on a yearly basis, but only at a rate that is in proportion 
to the Consumer Price Index.115
III.  THE FDA’S ROLE IN PROVIDING SAFE DRUGS 
The evolution of federal policy on the regulation of 
pharmaceutical drugs in the United States began in 1939 in 
response to numerous incidents of unsafe drugs infiltrating the 
country.116 Congress responded by directing the FDA to create a 
regulatory scheme that would ensure that Americans were not 
receiving drugs that would cause harm.117 Fifteen years later 
Congress expanded the scheme to ensure that the drugs were 
effective as well.118 Today, the United States has what has been 
called the “gold standard” for allowing only drugs that are safe 
and effective within its borders.119
111 Bob Nakagawa, Why Canadians Pay Less for Brand-Name Drugs and 
More for Generics, AARP RX WATCHDOG REPORT, Jan.-Feb. 2007, at 3. 
112 Id. 
113 Id. The seven countries are: France, Germany, Italy, Sweden, 
Switzerland, the United Kingdom and the United States. Id. 
114 Id. 
115 Id. 
116 Buyer Beware: The Danger of Purchasing Pharmaceuticals Over the 
Internet: Hearing Before the Permanent Subcomm. on Investigations of the S. 
Comm. On Governmental Affairs, 108th Cong. 227 (2004) [hereinafter 
Hearings] (statement of John M. Taylor, III Associate FDA Comm’r for 
Regulatory Affairs), available at http://www.fda.gov/ola/2004/ 
importeddrugs0722.html. 
117 Id. 
118 Id. 
119 Statement of the U.S. Food and Drug Administration Before the 
Nevada State Board of Pharmacy, (2006), available at http://www.fda.gov/ 
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A.  Federal Regulatory System 
Under the current regulatory system the FDA and state 
officials oversee every step of drug manufacture and distribution 
so consumers can rely on “product potency, purity and 
quality.”120 Furthermore, the FDA has several layers of 
protection to shield against drug quality or effectiveness being 
compromised.121 First, per the FDCA the FDA “maintains high 
standards for prescription drug approval.”122 In order for a drug 
to be approved the manufacturer must show that the product is 
“safe and effective” for its prescribed use.123 The product’s 
labeling must contain proper directions for use, and the drug 
must be manufactured only at certain facilities that are registered 
and approved by the FDA.124 After the drug has been approved 
the particular manufacturer is required to sustain compliance 
with cGMP’s “to ensure that the quality of the product is 
systematically evaluated throughout the manufacturing 
process.”125 The facilities where drugs are manufactured are 
also subject to random inspection by the FDA.126 After 
manufacture, the pharmacists or wholesalers responsible for 
drug distribution must be “licensed or authorized by the states in 
which they operate.”127
Perhaps most relevant to the drug reimportation debate is 
that there are few ways for drugs to enter the stream of 
oc/opacom/hottopics/importdrugs/stmt042006.html. 
120 Letter from Tommy Thompson, Secretary Department of Health and 
Human Services, to Senator James Jeffords (July 9, 2001) (on file with 
author), available at http://www.fda.gov/oc/po/thompson/medsact.html. 
121 Id. 
122 Id. 
123 Id. 
124 Id. 
125  Letter from Tommy Thompson, Secretary Department of Health and 
Human Services, to Senator James Jeffords (July 9, 2001) (on file with 
author), available at http://www.fda.gov/oc/po/thompson/medsact.html. 
126 Id. 
127 Id. 
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commerce.128 This measure protects against counterfeit or low 
quality drugs being placed into the distribution system.129 These 
safeguards protect the United States’ closed system of 
manufacture and distribution.130
Once a product leaves the closed system the FDA can no 
longer assure that the product is safe and effective for its 
intended use.131 Joe McCallion, a consumer safety officer in the 
FDA’s Office of Regulatory Affairs said; “If you buy drugs that 
come from outside the U.S., the FDA doesn’t know what you’re 
getting, which means safety can’t be assured.”132 Advocates of 
drug reimportation propose to open this closed system. 
However, the substantial risks identified by the FDA combined 
with the fact that HHS Secretaries past and present have opposed 
opening the closed system suggest that significant legislation 
allowing drug importation is unlikely. 
B.  Counterfeiting 
Although proponents of drug reimportation claim that 
safeguards in Canada will sustain the high level of security to 
which Americans have grown accustomed,133 there is evidence 
to the contrary. One of the biggest risks of drug reimportation is 
the potential for infiltration of counterfeit drugs into the 
distribution system.134 Due to the United States’ closed system, 
128 Id. 
129 Id. 
130 Letter from Tommy Thompson, Secretary Department of Health and 
Human Services, to Senator James Jeffords (July 9, 2001) (on file with 
author), available at http://www.fda.gov/oc/po/thompson/medsact.html. 
131 Id. 
132 Michelle Meadows, Imported Drugs Raise Safety Concerns, FDA 
CONSUMER MAGAZINE, Sept.-Oct. 2002 at 2, available at 
http://www.fda.gov/fdac/features/2002/502_import.html. 
133 Press Release, Office of the Governor, Blagojevich releases much-
anticipated report on feasibility and savings of prescription drug importation 
(Oct. 27, 2003) (on file with author), available at http://www.illinois.gov/ 
PressReleases/ShowPressRelease.cfm?SubjectID=3&RecNum=2346. 
134 See Donald G. McNeil Jr., In the World of Life-Saving Drugs, a 
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counterfeit drugs that have been an issue for other nations are 
not a significant problem in the United States.135
In 2001 the World Health Organization (“WHO”) estimated 
that between eight and ten percent of the world’s prescription 
drugs were counterfeit.136 Even though counterfeiting has been a 
rare phenomenon in the United States, attempts at bringing 
counterfeit drugs into the country have been on the rise.137 In 
order to combat the rise in counterfeiting the FDA has devoted 
more resources to preventing these products from entering the 
country.138 During the late 1990’s the FDA performed five 
counterfeit drug investigations per year.139 Since 2000 the FDA 
has increased the number of investigations to twenty per year.140
In response to increased counterfeiting, the FDA 
recommends stricter licensing requirements for distributors and 
implores those within the drug supply chain to refuse to do 
business with people of unknown backgrounds.141 These 
recommendations are directly contrary to a drug reimportation 
policy that would allow more people into the distribution 
system, all of whom would be outside the capability and 
authority of the FDA to monitor. 
C.  FDA Investigation and Enforcement 
Many of the FDA’s concerns about implementing an 
importation program have been buttressed by FDA “blitz 
exams” and undercover investigations. During the course of 
Growing Epidemic of Deadly Fakes, N.Y. TIMES, Feb. 20, 2007, at F1. 
135 Meadows, supra note 132, at 2. 
136 Letter from Tommy Thompson, Secretary Department of Health and 
Human Services, to Senator James Jeffords (July 9, 2001) (on file with 
author), available at http://www.fda.gov/oc/po/thompson/medsact.html. 
137 Protecting Consumers From Counterfeit Drugs, FDA CONSUMER 
MAGAZINE, May-June 2004 at 1, available at http://www.fda.gov/fdac/ 
features/2004/304_drug.html. 
138 Id. 
139 Id. 
140 Id. 
141 Id. 
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these investigations the FDA has gathered hard evidence that 
opening our borders to imported drugs heightens the risks for 
several potential problems including unapproved drugs and 
products that have been improperly packaged, labeled and 
stored. 
In July and November of 2003 the FDA conducted “blitz 
exams” which consist of examining shipments of foreign drugs 
bound for the United States.142 During a three day period at 
several different mail locations across the country, the FDA 
identified several problems.143
First, of 1,153 searched shipments, 88% contained 
unapproved drugs.144 Furthermore, the FDA seized twenty-five 
controlled substances, as well as drugs removed from the United 
States markets due to safety concerns.145 Finally, some drugs 
were not packaged properly.146 For instance, drugs were found 
shipped in tissue paper and sandwich bags.147
These blitzes identified several of the concerns raised with 
opening up the U.S. distribution system to foreign countries, 
such as labeling and storage. Often drugs imported from foreign 
countries are not labeled in English.148 This can cause 
significant problems for the consumer who will not likely 
understand the instructions on the label.149
Another problem is storage. Some drugs require specific 
storage conditions, like refrigeration, in order to work 
effectively.150 There is also no way to know if a particular drug 
was stored properly before it arrives in the United States. In 
fact, in 2003 the FDA discovered that CanaRx, a website that 
ships drugs from a Canadian pharmacy into the U.S., was 
142 Hearings, supra note 116. 
143 Id. 
144 Id. 
145 Id. 
146 Id. 
147 Hearings, supra note 116. 
148 Id. at 2. 
149 See id. 
150 Id. at 2. 
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shipping insulin, a drug needing refrigeration, in a “manner that 
did not satisfy the storage conditions specified in FDA approved 
labeling, and which could potentially compromise the safety and 
effectiveness of the insulin.”151 Similarly, in Rx Depot the court 
noted that the drugs obtained from Canada through Rx Depot 
did not have the FDA required patient package inserts, nor were 
they in FDA approved “unit of use packaging.”152 In the United 
States, this packaging is utilized to ensure “that certain drugs 
received by customers arrive in designated dosages with the 
approved patient package insert.”153 These examples highlight 
the concern that if drugs leave the “closed system,” once they 
re-enter there will be no way for either the authorities or the 
consumers to know if they have been properly stored along the 
way,154 which could compromise the drug’s effectiveness.155
Another significant issue concerns the possible interaction of 
imported drugs with other drugs a consumer may be ingesting. 
This is often referred to as “drugs with clinically significant 
drug-drug interactions.”156 There have been instances where the 
FDA has gone undercover and discovered that the proprietors of 
these websites will sell and send a particular drug even if they 
are aware that an individual is taking medication that will 
combine with the new medication to have adverse effects on the 
patient.157
During the blitzes in 2003 the FDA found many “foreign 
151 Id. at 14-15. 
152 United States v. Rx Depot, 290 F. Supp. 2d 1238, 1242 (N.D. Okla. 
2003). 
153 Id. 
154 Hearings, supra note 116. 
155 See id. at 2. 
156 Press Release, Food and Drug Admin., Recent FDA/U.S. Customs 
Import Blitz Exams Continue to Reveal Potentially Dangerous Illegally 
Imported Drug Shipments (January 27, 2004) (on file with author), available 
at http://www.fda.gov/bbs/topics/NEWS/2004/NEW01011.html. 
157 Press Release, Food and Drug Admin., FDA Test Results of 
Prescription Drugs from Bogus Canadian Website Show All Products Are 
Fake and Substandard (July 13, 2004) (on file with author), 
http://www.fda.gov/bbs/topics/news/2004/NEW01087.html. 
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versions” of FDA approved drugs.158 “Foreign versions” of 
FDA approved drugs are similar to the drugs approved by the 
FDA but may deviate from the FDA approved version in 
“potency and purity.”159 Moreover the FDA cannot assure the 
“safety and efficacy” of these drugs because the FDA has “not 
monitored the manufacturing and quality control processes of the 
facility in which the product was produced.”160 These “foreign 
versions” are illegal in the United States because they are not 
approved by the FDA, but purport to be the same as an FDA 
approved version.161
There were at least six drugs found during the blitzes that 
require professional supervision.162 For example, APO-Warfarin 
was discovered during a November 2003 blitz.163 This is a 
“foreign version” of the blood thinner, warfarin.164 According 
to the FDA, “the potency of warfarin may vary depending on 
how it is manufactured, and the drug must be carefully 
administered and monitored by a health professional in order to 
prevent serious bleeding problems.”165 This seized drug is 
illustrative of several problems. First, since the drug was sent 
from another country there is no way to ensure that the drug is 
taken with a doctor’s supervision. If the drug had been 
prescribed by a physician in the United States, the physician 
could make certain that the patient was given only a safe 
amount, necessitating another trip to the doctor for more 
medication. Since this drug left the “closed system” there is also 
no way for the FDA to know the exact potency of each dose 
158 FDA News: Recent FDA/US Customs Import Blitz Exams Continue 
to Reveal Potentially Dangerous Illegally Imported Drug Shipments, supra 
note 151. 
159 Id. 
160 Id. 
161 Id. 
162 Id. 
163 FDA News: Recent FDA/US Customs Import Blitz Exams Continue 
to Reveal Potentially Dangerous Illegally Imported Drug Shipments, supra 
note 151. 
164 Id. 
165 Id. 
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since it varies depending on the manufacturer.166
In addition to blitzes, the FDA has conducted undercover 
investigations into the illegal importation of drugs from Canada, 
and has found significant threats to the public health.167 In 
February and August 2004 the FDA made undercover purchases 
from Canada Care, a company engaged in the importation of 
drugs into the United States from Canada.168 In this particular 
undercover investigation the FDA purchased both Sporanox and 
Neurontin.169 Instead of receiving Neurontin, the undercover 
agent was sent two drugs that are unapproved by the FDA, 
APO-Gabapentin and Novo-Gabapentin.170 Since the drugs 
received are not approved, the FDA cannot “assure the safety 
and efficacy” of these drugs.171 Furthermore the FDA has no 
information on how the drugs are made, what information is 
included with the drug or possible side effects of the drug.172 
Thus, the drugs are “more likely to be contaminated, 
counterfeit, inherently ineffective, or contain different amounts 
of the active ingredients from similar drugs that have been 
reviewed and approved by the FDA.”173
The shipment of Sporanox did contain the FDA approved 
version of the drug, but the method of shipment caused the FDA 
166 Press Release, Food and Drug Admin., Recent FDA/U.S. Customs 
Import Blitz Exams Continue to Reveal Potentially Dangerous Illegally 
Imported Drug Shipments (January 27, 2004) (on file with author), available 
at http://www.fda.gov/bbs/topics/NEWS/2004/NEW01011.html. 
167 Press Release, Food and Drug Admin., FDA Takes Action Against 
Company for Illegal Importation of Unapproved, Potentially Unsafe Drugs 
(December 1, 2004) (on file with author), available at http://www.fda.gov/ 
bbs/topics/news/2004/NEW01142.html. 
168 Id. 
169 Id. 
170 Id. 
171 Id. 
172  Press Release, Food and Drug Admin., FDA Takes Action Against 
Company for Illegal Importation of Unapproved, Potentially Unsafe Drugs 
(December 1, 2004) (on file with author), available at http://www.fda.gov/ 
bbs/topics/news/2004/NEW01142.html. 
173 Id. 
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to consider it a “potentially serious health threat.”174 Normally 
Sporanox is taken in one week “pulses.”175 Patients then wait 
three weeks before continuing with another “pulse” treatment.176 
In between the “pulses” a patient is supposed to consult with his 
doctor to determine whether the treatment should continue or 
terminate.177 Termination would be due to the patient 
experiencing side effects that could potentially damage his heart 
or liver.178 The Canadian pharmacy sent the undercover agent 
three packages of Sporanox, potentially allowing the patient to 
consume two “pulses” without consulting a physician in 
between.179 This could result in serious side effects, including 
fatality.180 Accordingly, in Rx Depot, the court found that 
“[p]rescription drugs obtained through Rx Depot frequently are 
dispensed in greater quantities than are requested by the 
prescribing physician.”181 Additionally, Rx Depot dispensed 
drugs in preset amounts regardless of the patient’s prescribed 
quantity, and “without directions to take the drug for only the 
number of days prescribed by the U.S. physician.”182 The 
findings of this undercover investigation are particularly 
significant because legalizing drug reimportation could lead to 
the exact consequences the FDA fears. If citizens are allowed to 
legally import drugs from Canada, or other countries, the drugs 
they receive will be outside the FDA’s regulatory scheme and 
this could lead to dangerous consequences. 
174 Id. 
175 Id. 
176 Id. 
177  Press Release, Food and Drug Admin., FDA Takes Action Against 
Company for Illegal Importation of Unapproved, Potentially Unsafe Drugs 
(December 1, 2004) (on file with author), available at http://www.fda.gov/ 
bbs/topics/news/2004/NEW01142.html. 
178 Id. 
179 Id. 
180 Id. 
181 United States v. Rx Depot, 290 F. Supp. 2d 1238, 1242 (N.D. Okla. 
2003). 
182 Id. 
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IV.  STATE PROGRAMS 
The clamoring for an importation program has come largely 
from state governors looking for ways to save money and satisfy 
citizens frustrated by high drug costs. As noted in Part II, 
several states, including Minnesota and Wisconsin, have 
established websites that will link citizens to websites selling 
drugs from Canada.183 Unfortunately some of these programs 
have not worked as effectively as the state governments had 
hoped. In fact, in many instances, these programs have 
demonstrated the importance of sustaining the closed distribution 
system.184
Research by the state of Minnesota exposed several problems 
with how drugs are distributed and produced in Canada.185 
During a pre-announced visit to Canada, Minnesota officials 
noticed that many pharmacies used “unsupervised technicians, 
not trained pharmacists, to enter medication orders and to try to 
clarify prescription questions.”186 Furthermore one of the 
pharmacies the officials visited had its pharmacists “review 100 
new prescriptions or 300 refill prescriptions per hour, a volume 
so high it would have been impossible to assure safety.”187 The 
issue of proper labeling188 was not a priority for at least one 
pharmacy who did not label any of its products, choosing 
instead to send the labels along unattached, even to those 
customers who were receiving more than one prescription.189 
Even more troubling, the Minnesota officials noted that many 
products that required refrigeration were being shipped un-
refrigerated.190
Moreover, the state of Wisconsin had similar problems when 
183 Hearings, supra note 116. 
184 See id. 
185 Id. 
186 Id. 
187 Id. 
188 See supra Part III.C. 
189 Hearings, supra note 116. 
190 Id. 
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it reviewed reports presented by the three Canadian pharmacies 
it linked to via its website.191 Wisconsin officials found that 361 
of the 765, or 41%, of the prescriptions filled by the Canadian 
pharmacies violated the terms of the agreement made between 
the pharmacies and the state.192 “Specifically, 127 of the 
dispensed drugs were products not approved by FDA or 
available in the U.S., while 189 of the drugs were products not 
authorized by the state program.”193 Additionally, in six 
instances the pharmacies mistakenly sent drugs that required 
refrigeration in the mail.194 The state of affairs became so 
drastic that the Wisconsin Department of Health and Family 
Services mailed letters to all three pharmacies demanding they 
stop these practices.195 Even more revealing is this statement 
from the executive director of the Wisconsin Pharmacy Society: 
“no one in Wisconsin has any real idea what these Canadian 
businesses are doing.”196
These studies are significant because many proponents of 
drug reimportation maintain that Canadian safety measures are 
on par with the best in the world.197 In addition to the findings 
of both Minnesota and Wisconsin, in August 2005 the FDA 
performed an investigation at airports in New York, Los 
Angeles and Miami “which found that nearly half of the 
imported drugs the FDA intercepted from four selected countries 
were shipped to fill orders that consumers believed they were 
placing with ‘Canadian pharmacies.’”198 It turned out that 85% 
191 Id. 
192 Id. 
193 Id. 
194 Hearings, supra note 116. 
195 Id. 
196 Id. 
197 Press Release, Office of the Governor, Blagojevich releases much-
anticipated report on feasibility and savings of prescription drug importation 
(Oct. 27, 2003) (on file with author), http://www.illinois.gov/PressReleases/ 
ShowPressRelease.cfm?SubjectID=3&RecNum=2346. 
198 Press Release, U.S. Food and Drug Admin., FDA Warns Consumers 
Not to buy or Use Prescription Drugs from Various Canadian Websites that 
Apparently Sell Counterfeit Products (August 30, 2006) (on file with author), 
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of the drugs being promoted as “Canadian” actually came from 
27 other countries around the world.199 The findings of this 
investigation drive home the importance of sustaining a closed 
distribution system and indicate that many internet sites that 
claim to be “Canadian” are in fact selling drugs of unknown 
“origin, safety and efficacy.”200
When officials from New Hampshire Governor Craig 
Benson’s office traveled to the on site location of 
CanadaDrugs.com they found conditions that were later termed 
“significant safety issues.”201 Moreover as part of the “terms of 
service” for this site “purchasers . . . agree that they ‘will not 
be liable for damages arising from personal injury or death’ 
from the use of drugs sold by the pharmacy.”202 As a result a 
consumer would have no remedy vis a vis CanadaDrugs.com for 
“injuries arising from the use of drugs from this shipper.”203 
Presumably the lack of legal remedy would lead to the increase 
in insurance. This is significant because the biggest advantage 
drug reimportation is purported to have is the opportunity to 
save Americans money. The ability of importation to save 
Americans money is one of the two considerations the HHS 
Secretary is mandated to take into account when considering 
whether to implement drug importation per the MMA.204 
Therefore an increase in insurance costs could potentially 
mitigate any savings a comprehensive drug reimportation plan 
would bear. 
V.  THE PHARMACEUTICAL LOBBY 
The pharmaceutical industry has used its vast resources, 
including spending a significant amount of money on political 
available at http://www.fda.gov/bbs/topics/NEWS/2006/NEW01441.html. 
199 Id. 
200 Id. 
201 Hearings, supra note 116. 
202 Id. 
203 Id. 
204 Medicare Prescription Drug, Improvement and Modernization Act of 
2003, Pub. L. No. 108-173, § 804(b) (2003). 
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donations, to influence politicians and hire lobbyists to advocate 
on its behalf.205 The pharmaceutical industry has achieved 
significant legislative victories, as seen in the Medicare 
Modernization Act of 2003 and patent extensions, and the 
industry is expected to fight importation with the same vigor.206
A.  Pharmaceutical Industry Resources 
The pharmaceutical lobby has been called an “elephant 
among chickens”207 because of its influence and ability to 
achieve its desired results.208 In fact, pharmaceutical 
manufacturers spend money on lobbying efforts and campaign 
contributions at a rate that exceeds almost any other industry.209 
In 2003 the pharmaceutical industry’s trade group, The 
Pharmaceutical Research and Manufacturers of America 
(“PhRMA”) spent $8.5 million on lobbying.210 Furthermore, 
several PhRMA members have their own lobbying budget in the 
millions of dollars.211 For instance, in only the first six months 
of 2003 Eli Lilly and Co. spent $2.9 million on lobbying 
services, Bristol-Myers Squibb spent $2.6 million, Johnson & 
Johnson $2.2 million, Hoffmann-LaRoche $2 million and Pfizer 
$1.8 million.212 In sum, the pharmaceutical industry spent over 
$29 million in the first half of 2003, when the drug 
reimportation debate was at its apex.213 From 1998 to 2004 
pharmaceutical and health care product companies spent more 
205 See infra Part V.A. 
206 See infra Part V.C. 
207 Greg Gordon, Drug Firms Flex their Political Muscle, STAR TRIB. 
(Minn.), Aug. 27, 2000, at 1A. 
208 See id. 
209 Frederic J. Frommer, Drug Lobby Wages War on Imports, 
Associated Press, Oct. 13, 2003, available at http://www.cbsnews.com/storie
s/2003/10/15/politics/main578173.shtml. 
210 Id. 
211 Id. 
212 Id. 
213 Id. 
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than $675 million on federal lobbying.214 This figure exceeded 
the industry with the second most expenditures by almost $80 
million.215 Moreover, these figures do not take into account the 
money spent on campaign contributions from these companies 
and their Political Action Committees (“PAC”).216
During the 2003-2004 election cycle, the pharmaceutical 
industries combined expenditures on campaign contributions and 
lobbying was $818 million; second most of any industry.217 In 
the 2003-2004 election cycle, Pfizer’s PAC contributed 
$2,261,777 to various candidates and committees.218 In the 
2005-2006 cycle that number rose to $3,241,156.219 In addition, 
Eli Lilly’s PAC contributed $1,678,376 in 2003-2004 and an 
additional $1,565,336 in 2005-2006.220 These numbers are 
particularly significant considering federal election law only 
allows a PAC to contribute $5,000 dollars each election cycle to 
any particular candidate.221
The pharmaceutical industry provides politicians with 
additional benefits beyond just campaign donations. In addition 
to the $161,000 that Senator Joe Lieberman received in 
campaign donations from 1993 up to his vice-presidential run in 
2000, Lieberman also flew on Pfizer’s corporate jet and made a 
speech before PhRMA’s membership.222 The pharmaceutical 
industry paid for events at both the Democratic and Republican 
conventions in 2000, including a “Mardi Gras-style gala” on the 
sets of Paramount studios in Los Angeles for the Democratic 
214 Alison Lapp, Drug Lobby Forks Out a Fortune; Pharmaceutical 
Industry Outspends All Others to Get Its Way in Washington, THE HERALD-
SUN, July 17, 2005, at B1. 
215 Id. 
216 See id. 
217 Lapp, supra note 214. 
218 Federal Election Commission, http://herndon1.sdrdc.com/cgi-bin/ 
ancomsrs/?_04+C00016683 (last visited Nov. 30, 2006). 
219 Id. 
220 Id. 
221 2 U.S.C. § 441a (2002). 
222 Greg Gordon, Drug Firms Flex their Political Muscle, STAR TRIB. 
(Minn.), Aug. 27, 2000, at 1A. 
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convention.223 The industry also contributed $625,000 to the 
Bush-Cheney inaugural committee.224 Industry companies paid 
for tens of millions of dollars worth of television and radio ads 
on behalf of a non-profit group that was attacking President 
Clinton’s proposal for a “government-run prescription drug 
program.”225
B.  Industry Manpower 
Not only does the pharmaceutical industry have significant 
resources, but it uses those resources to wield a great deal of 
influence. In 2004 PhRMA hired former Congressman Billy 
Tauzin to become the president and CEO of its organization.226 
This hire was particularly controversial and drew the ire of 
Democrats and public advocacy groups, because Tauzin was 
being considered for the job while he was still chairman of the 
House Energy and Commerce Committee, which has 
“regulatory oversight of the pharmaceutical industry.”227 
Furthermore, Tauzin and the committee he chaired played a 
critical role in constructing the Medicare Modernization Act of 
2003228 which has been lauded as a rousing success for the drug 
industry.229
In 2001 more than half of the pharmaceutical industry’s 625 
lobbyists were former members of Congress, former 
223 Id. 
224 Leslie Wayne, A Muscular Lobby Rolls Up Its Sleeves, N.Y. TIMES, 
Nov. 4, 2001, at Money and Business, p. 1. 
225 Gordon, supra note 222, at 1A. 
226 Tauzin Tapped To Become PhRMA’s New Chief, WASH. DRUG 
LETTER (FDA News, Falls Church, VA), Dec. 20, 2004, Vol. 36 No. 5 at 9. 
227 Id. 
228 Id. 
229 M. Asif Ismail, Drug Lobby Second to None: How the 
Pharmaceutical Industry Gets its Way in Washington, The Center for Public 
Integrity, available at http://www.publicintegrity.org/rx/report.aspx? 
aid=723; M. Asif Ismail, FDA: A Shell of its Former Self, The Center for 
Public Integrity, available at http:www.publicintegrity.org/rx/report.aspx? 
aid=722. 
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Congressional staff members and former government 
officials.230 Former Secretary of Defense Donald Rumsfeld was 
once chief executive at the drug company G.D. Searle.231 Not 
only are there hundreds of pharmaceutical lobbyists, but they are 
also broadly dispatched. The drug industry lobbied at least 1,600 
bills from 1998-2004.232
C.  Industry Influence and Victories 
As illustrated above the pharmaceutical industry spends a 
great deal of money with the intent of influencing politicians and 
political candidates. Of course, these companies would not 
consistently dole out millions of dollars if these tactics were 
ineffective. The pharmaceutical lobby began in earnest in the 
1960’s after the creation of Medicare and gained widespread 
attention for its efforts and influence in defeating President 
Clinton’s health care plan in the 1990’s.233 Perhaps the effort 
that best demonstrates the pharmaceutical lobby’s ability to 
wield influence is its lobbying of the Medicare Modernization 
Act (MMA) of 2003. That legislation, which went into effect in 
2006, created a prescription drug benefit for seniors that was 
funded by taxpayer dollars.234 The remarkable aspect of the bill 
is that despite the fact that it created a reliable market of 41 
million customers235 for the pharmaceutical industry, there was 
still a provision in the bill that prohibited the government from 
negotiating lower prices with pharmaceutical companies.236
This provision was not included in the MMA to prevent drug 
230 Wayne, supra note 224. 
231 Id. 
232 M. Asif Ismail, Drug Lobby Second to None: How the 
Pharmaceutical Industry Gets its Way in Washington, The Center for Public 
Integrity, available at http: www.publicintegrity.org/rx/report.aspx?aid=723. 
233 See Wayne, supra note 224. 
234 Medicare Prescription Drug, Improvement and Modernization Act of 
2003, Pub. L. No. 108-173, § 101 (2003). 
235 Ismail, supra note 232. 
236 Medicare Prescription Drug, Improvement and Modernization Act of 
2003, Pub. L. No. 108-173, § 222 (2003). 
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companies from losing money because drug companies actually 
stand to make a huge profit.237 Analysts at Goldman Sachs 
predict that the MMA will result in a 9% increase in profits for 
drug companies.238 This percentage represents $13 billion per 
year.239 Furthermore, a Boston University study on the impact 
of the MMA predicted that 61% of the Medicare money spent 
on prescription drugs will turn directly into profit for the drug 
companies.240 In addition, the study predicts that drug 
companies will see increased profits of $139 billion over an 
eight year period.241 The positive impact the MMA will have on 
drug industry profits demonstrates the success of the industry’s 
lobbying efforts. In fact, Helen Savage of the North Carolina 
state office of AARP said, “[t]he lack of effective cost 
containment or price controls for prescription drugs in the 
Medicare Modernization [of 2003] reflects the strength of the 
pharmaceutical lobby.”242
Perhaps as significant as what the drug companies gained via 
the passage of the MMA is what they avoided. Despite polls that 
showed a majority of Americans supported drug reimportation, a 
provision allowing full scale importation was not included in the 
MMA.243 Moreover, other provisions the drug industry strongly 
objected to were not in the bill, such as government price 
controls that have proven effective in Canada for reducing drug 
prices and increased access to the marketplace for generic 
drugs.244 Both price controls and greater access to generics 
would likely have the effect of driving drug costs down, yet 
237 Ceci Connolly, Drugmakers Protect Their Turf: Medicare Bill 
Represents Success for Pharmaceutical Lobby, WASH. POST, Nov. 21, 2003, 
at A4. 
238 Id. 
239 Id. 
240 Ismail, supra note 232. 
241 Id. 
242 Alison Lapp, Drug Lobby Forks Out a Fortune; Pharmaceutical 
Industry Outspends All Others to Get Its Way in Washington, THE HERALD-
SUN, July 17, 2005, at B1. 
243 Connolly, supra at note 237. 
244 Id. 
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these provisions proved elusive.245 Of the MMA one Republican 
close to the drug industry said, “In their [drug industry] view, 
by improving access for all seniors, we will ameliorate any 
pressure on the industry toward price controls or 
reimportation.”246
The MMA illustrates the influence exerted by the drug 
industry in Washington, and such success is not an aberration. 
For instance at the end of 2001 Congress passed the Best 
Pharmaceuticals for Children Act that extended patents on 
certain drugs by six months.247 The impetus for this measure 
was the fear of an anthrax attack and the government’s desire to 
stockpile Cipro,248 an antibiotic used to treat anthrax 
exposure.249
Just prior to passing the Best Pharmaceuticals for Children 
Act, Bayer, the manufacturer of Cipro, agreed to give the 
government a 46% discount on the first 100 million doses of 
Cipro sold, saving the government $82 million.250 Not 
coincidentally, the 2001 bill had provisions that were favorable 
to Bayer.251 In fact, the bill permitted a six month extension on 
certain drug patents, including Cipro, in return for drug 
companies performing tests on these drugs to ensure their safety 
and efficacy in children.252
Some groups have argued that safe use for children should 
be part of the FDA approval process in the first place, before a 
drug can be obtained in the marketplace.253 Additionally, the 
245 Id. 
246 Id. 
247 S. 1789 § 7, 106th Cong. (2001) (enacted). 
248 See Patently Offensive: Congress Set to Extend Monopoly Patents for 
Cipro and Other Drugs, Public Citizen, http://www.Citizen.org/ 
print_article.cfm?ID=6435. 
249 Wayne, supra note 224. 
250 Cipro Saga Exposes how Drugmakers Protect Profits, USA TODAY, 
Oct. 29, 2001. 
251 See Connolly, supra note 237. 
252 S. 1789 § 7, 107th Cong. (2001) (enacted). 
253 Patently Offensive: Congress Set to Extend Monopoly Patents for 
Cipro and Other Drugs, Public Citizen, http://www.Citizen.org/ 
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amount of money drug companies gain through patent extension 
greatly exceeds the amount of testing.254 According to a study 
performed by the Tufts Center for the Study of Drug 
Development, pediatric testing costs an average of $3.87 million 
per drug. Per this legislation the FDA requested testing on 188 
drugs, putting the total cost of testing at $727 million.255 The 
patent extensions were expected to give patent holding 
companies an additional $29.6 billion in additional sales, 
handing each company an additional $592 million per year in 
added profits.256 Thus, the amount in added sales is forty times 
the cost of testing,257 a veritable windfall for the drug 
companies. Eli Lilly and Company was able to make an 
additional $900 million in revenue on the anti-depressant, 
Prozac, because of the six month patent extension.258 In 
addition, Bayer stood to gain an additional $358 million thanks 
to the extension.259 Thus, Bayer would recover all of their $3.7 
million in lobbying expenses from 1999-2001 in a mere two 
days.260 Not surprisingly, the bill’s sponsors, Senator Chris 
Dodd and Senator Mike DeWine, received the third and seventh 
highest contributions, respectively, from drug companies among 
senators from 1990-2000.261
The losers in this political exchange are U.S. consumers. 
The longer drug patents are extended, the longer cheaper, 
generic manufacturers are excluded from the marketplace.262 
This particular patent extension cost consumers $14 billion over 
print_article.cfm?ID=6435. 
254 Id. 
255 Id. 
256 Id. 
257 Id. 
258 Maureen Groppe, Departing Congress Treated Drug Companies Well, 
GANNETT NEWS SERVICE, Nov. 28, 2002. 
259 Patently Offensive: Congress Set to Extend Monopoly Patents for 
Cipro and Other Drugs, Public Citizen (2001), http://www.Citizen.org/ 
print_article.cfm?ID=6435. 
260 Id. 
261 Id. 
262 See Wayne supra note 224. 
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what generics would have cost.263
Protecting and extending patents is one of the primary goals 
of the pharmaceutical industry and it has been very effective in 
getting results. In 2003, the World Trade Organization was 
forced to appease the drug industry because the Bush 
administration, fiercely supporting the industry, would not sign 
an agreement that may have compromised drug industry profits, 
even in the face of desperate need for humanitarian aid.264 In the 
face of AIDS, malaria and tuberculosis epidemics in Africa, the 
WTO tried to respond with worldwide agreement to get less 
expensive drugs to those in Africa who badly need them.265 The 
United States government rejected the initial proposal, saying 
that the agreement should be limited to only a small number of 
countries and apply to only a few diseases.266 The rationale for 
this position was that impoverished nations would somehow 
exploit multi-national drug companies, whose profits are among 
the largest in the world.267 Every other country that was home 
to a major pharmaceutical company was willing to sign the 
agreement.268 In fact, an Indian pharmaceutical company, Cipla, 
was willing to sell AIDS drugs to African countries for 4% of 
the price charged by multi-national companies.269 The final 
agreement included the Bush administration’s demands that 
“generic medicines could be imported to cure any life-
threatening disease, so long as it was a public health 
emergency” and provisions that would ensure countries would 
not take advantage of the reduced costs for commercial profit 
263 Wayne, supra note 224. 
264 Elizabeth Becker, Cheaper Medicines for World’s Poor; Trade Rules 
Altered on Patented Drugs, INT’L HERALD TRIB., Sept. 2, 2003 at 1. 
265 Id. 
266 Id. 
267 See Id. 
268 Becker, supra note 264. 
269 Aravind Adiga, Prescription For Profits; India’s generic-drug makers 
are flooding international markets with cheap copycat pills, infuriating 
behemoth rivals from the U.S. and Europe, TIME ASIA, Sept. 22, 2003, at 
44. 
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instead of meeting public health needs.270
Critics railed against the United States accusing the Bush 
administration of including too much “bureaucratic red tape” 
that would “doom” the effective implementation of the 
agreement.271 Ellen Hoen of Doctors Without Borders said the 
“deal was designed to offer comfort to the U.S. and the Western 
pharmaceutical industry. Unfortunately, it offers little comfort 
for poor patients. Global patent rules will continue to drive up 
the price of medicines.”272
The drug industry’s relationship with the federal government 
has serious health implications besides those in Africa. For 
instance, in 1992 the Prescription User Fee Act streamlined the 
process of bringing life-saving drugs into the marketplace, with 
the condition that companies are required to perform follow up 
studies to prove that these drugs are safe.273 Additionally in 
1997, Congress passed the FDA Modernization Act, which 
lowered the standards for approving new drugs.274 Some drugs 
were only required to be tested in one clinical trial “to show that 
the drug was reasonably safe and effective.”275
Both pieces of legislation were helpful to the drug industry 
but have proven problematic in practice. Marcia Angell, M.D., 
a former editor in chief of the New England Journal of 
Medicine, called the FDA Modernization Act, “a bundle of gifts 
to the pharmaceutical industry.”276 Angell went on to say, 
“[a]mong other gifts was a dropping of standards for approving 
new drugs.”277 The consequences of reduced standards have 
been severe. For instance, Merck’s painkiller Vioxx is estimated 
270 Becker, supra note 264. 
271 Id. 
272 Id. 
273 M. Asif Ismail, FDA: A Shell of its Former Self: The Food and Drug 
Administration lacks the power to regulate pharmaceuticals and keep you 
safe, The Center for Public Integrity, http://www.publicintegrity.org/rx/ 
report.aspx?aid=722. 
274 Id. 
275 Id. 
276 Id. 
277 Id. 
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to have caused 140,000 heart attacks and 55,000 deaths in the 
United States.278 Additionally, many drug companies are not 
performing the follow up tests that are required by law and the 
FDA simply does not have the resources to ensure the tests take 
place.279 A study performed by Congressman Ed Markey’s 
office found that half of the post marketing studies that should 
have begun, have not started, despite the fact that companies 
have been selling the drugs for an average of twenty months.280 
In one instance the companies had been selling the drug for six 
years and nine months with no testing.281
The FDA does not have the resources to monitor drug 
companies at the rate with which they are able to get drugs 
approved.282 For example, Pfizer’s revenue went from $11.3 
billion in 1996 to $52 billion in 2004.283 On the other hand the 
FDA’s budget was only $1.7 billion in 2004.284 Moreover, in 
2005 the FDA employed 11,000 people, only a slight increase 
from the 8,200 that were employed by the agency twenty-five 
years ago.285 Thus, the great disparity in resources only serves 
to exacerbate the effectiveness in getting drug companies the 
results they desire. 
Furthermore, given the FDA’s limited resources, it is 
difficult to understand how an expanded regulatory scheme, via 
drug reimportation would be viable. Even if proponents of drug 
reimportation are willing to sacrifice some degree of safety in 
return for a reduction in prices, without a significant and 
probably costly expansion of FDA resources, it seems likely that 
comprehensive drug reimportation would rely almost solely on 
the safety provisions of other countries. Although there are no 
reported instances of Americans being injured due to 
278  Ismail, supra note 266. 
279 Id. 
280 Id. 
281 Id. 
282 Id. 
283 Ismail, supra note 266. 
284 Id. 
285 Id. 
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consumption of Canadian pharmaceuticals, the idea of relying on 
another country to provide millions of American citizens with 
drugs is a daunting proposition. 
It seems clear that the “worst case scenario” of drug 
reimportation would involve evil doers infiltrating a foreign drug 
source and importing drugs to America. In one of the stranger 
ploys by the pharmaceutical industry, PhRMA was reported to 
have attempted to commission a fiction novel designed to scare 
people away from drug reimportation.286 PhRMA even admits to 
considering the idea, but says they ultimately decided against 
funding the project.287 The novel was going to involve a 
terrorist organization that uses Canadian pharmaceutical websites 
to murder millions of American customers.288 Kenin Spivak, 
who was to co-write the abandoned project said, “they wanted 
lots of people to die.”289 Although playing on people’s worst 
fears to curry political favor in such a clandestine manner is 
abhorrent, the prospect of opening America’s borders to drugs 
of unknown sources just five years removed from terrorist 
attacks on U.S. soil and with counterfeiting on the rise290 is 
unnerving. Even without PhRMA support, the novel is due out 
next year291 and although it is a work of fiction, opening the 
“closed system” seems to at least make the premise a real life 
possibility. 
VI.  LOOKING AHEAD 
As the 2008 presidential election nears, solutions to high 
drug costs will likely receive greater public attention. In fact, 
legislation passed at the end of 2006 that allows Americans to 
carry a moderate amount of drugs into the United States from 
286 Lloyd Grove, Drug Business Prescribes A Novel Cure For its Ills, 
N.Y. DAILY NEWS, Oct. 17, 2005, at 24. 
287 Id. 
288 Id. 
289 Id. 
290 Protecting Consumers From Counterfeit Drugs, FDA CONSUMER 
MAGAZINE, May-June 2004 at 1. 
291 Grove, supra, note 286. 
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Canada should raise the temperature of the debate.292 In 
addition, the results of the 2006 mid-term elections have left 
some reimportation supporters optimistic that a comprehensive 
reimportation plan may be implemented.293 However, these 
reimportation advocates may be disappointed, as there remains 
the possibility that legislators will instead focus their efforts on 
modifying the MMA as a means of reducing drug costs.294 Even 
if modification of the MMA is unsuccessful there remain several 
alternatives that do not include the importation of drugs from 
foreign countries.295
A.  2007 Homeland Security Appropriations Bill 
In the fall of 2006, Congress passed the 2007 Homeland 
Security appropriations bill which included a provision that 
would allow Americans to personally transport as much as a 90 
day supply of FDA approved drugs from Canada.296 This 
measure has been lauded as indicative that more meaningful 
drug reimportation is inevitable, prompting Congressman David 
Vitter to say, “[n]ow it is only a matter of time before we pass a 
comprehensive drug reimportation bill.”297 Although it is true 
that this provision allows drugs to be legally imported from 
Canada, Congressman Vitter’s rhetoric is overly simplistic. 
First, this legislation only allows an individual to personally 
292 See 2007 Homeland Security appropriations bill, Pub. L. No. 109-
295 § 535 (2006). 
293 See Press Release, Office of Senator David Vitter, U.S. Senator 
David Vitter Scores Major Victory for Drug Reimportation (Sept. 27, 2006) 
(on file with author), 
http://vitter.senate.gov/?module=PressRoom/PressItem&ID= 5ce075ed-62fd-
4f7d-bf28-772b6529b780. 
294 See infra Part VI.C. 
295 See infra Part VI.D. 
296 2007 Homeland Security appropriations bill, Pub. L. No. 109-295 § 
535 (2006). 
297 Press Release, Office of Senator David Vitter, U.S. Senator David 
Vitter Scores Major Victory for Drug Reimportation (Sept. 27, 2006) (on file 
with author), http://vitter.senate.gov/?module=PressRoom/PressItem&ID= 
5ce075ed-62fd-4f7d-bf28-772b6529b780. 
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purchase their drugs in Canada.298 The only citizens that will 
benefit in a meaningful way are those that live close enough to 
Canada to make traveling across the border more cost effective 
than simply buying drugs in the United States. Particularly 
ironic is that Congressman Vitter is a Representative of the State 
of Louisiana, a state so far from the Canadian border299 that it is 
hard to imagine a trip to Canada for a 90 day supply of drugs 
being cost effective for any resident of that state. 
Moreover, those most in need of prescription drugs, senior 
citizens, may not benefit from this legislation because the bill 
requires an individual to personally purchase the drugs in 
Canada.300 It seems likely that many senior citizens will be 
physically unable to travel north to purchase drugs. 
Furthermore, there will inevitably be a group of people who find 
it inefficient to travel to Canada to buy drugs for only a 90 day 
supply. Although this legislation will certainly help some people 
gain access to cheaper drugs in Canada, the scope of this 
legislation is very narrow and can hardly be considered 
suggestive that full scale drug reimportation for the entire 
country is imminent. 
Additionally, as previously discussed, the drug industry has 
demonstrated the ability to make small concessions in order to 
achieve its overall goals.301 This kind of savvy was seen in their 
handling of the MMA, patent extensions and in dealing with the 
WTO.302 Thus, there is good reason to be skeptical that pro-
reimportation members of Congress will be successful in 
asserting their agenda. A more comprehensive reimportation 
program would inevitably be met with massive resistance by the 
drug industry and would involve overcoming all the hurdles 
already discussed.303
298 Pub. L. No. 109-295 § 535 (2006). 
299 Mapquest.com places the distance from New Orleans, LA to Beebe 
Plain, VT at 1,681.42 miles. 
300 Pub. L. No. 109-295 § 535 (2006). 
301 See supra Section V.C. 
302 Id. 
303 See supra Part V. 
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B.  2006 Mid-Term Elections 
The 2006 mid-term elections gave Democrats a majority in 
the House and Senate304 and have left many importation 
advocates feeling optimistic about the prospects for a 
comprehensive reimportation plan.305 Democrats have tried to 
strengthen their position for implementing drug reimportation by 
adding reimportation advocates, Senators Sherrod Brown, Bernie 
Sanders and Barack Obama to the Senate Health Committee.306 
Although Democrats view reimportation more favorably than 
Republicans, Democrats hold only a slight majority in both 
houses of Congress and any comprehensive plan could be vetoed 
by President Bush, who has consistently been against 
reimportation because of the safety concerns expressed by the 
FDA and HHS Secretaries past and present.307 Of more pressing 
concern to Democrats could be modification of the MMA.308 
Thus, it would be difficult for Congress to also initiate drug 
reimportation considering the heavy opposition that can be 
expected to both reimportation and price negotiations. 
C.  Modification of the MMA 
In fact the prescription drug benefit included in the MMA, 
known as Part D,309 may be ripe for modification and could 
304 Charles Babington, New Congress Unlikely to Rush Toughest Issues, 
WASH. POST, Nov. 11, 2006, at A3. 
305 Maria Bartiromo, Should Business Be Worried?, BUSINESS WEEK, 
Nov. 20, 2006, at 122l; Josh Fischman, Health’s Ailment, U.S. NEWS & 
WORLD REP., Nov. 20, 2006. 
306 New Health Committee Members May Push Biogenerics, 
Reimportation, INSIDE CMS (FDA News, Falls Church, VA), Nov. 16, 
2006, Vol. 9 No. 23. 
307 See Seay, supra note 4. 
308 See Fischman, supra note 305. 
309 Kara Gavin, Study: Senior Medicare drug costs vary widely among 
states, University of Michigan News Service, http://www.umich.edu/ 
~urecord/0607/Jan22_07/18.shtml. “Medicare Part D which took effect 
January 2006 . . . offers prescription drugs to seniors and people with certain 
disabilities.” Dan McLean, Seniors Share Concerns with Sanders, 
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potentially quiet clamoring for importation. The success of Part 
D and its ability to provide affordable drugs to those who might 
otherwise favor importation will be a critical issue in whether 
the importation debate gains steam or dissipates.310 Even as 
currently constituted, Part D is saving the average beneficiary 
55%.311 One of the problems with the MMA is that the cost of 
drugs is distributed unevenly throughout the country.312 A recent 
study at the University of Michigan found that “the plan reduces 
costs for some seniors more than others, depending on where 
they live.”313 An individual in a given state, taking the same 
drugs, could be paying thousands more than someone in a sister 
state.314 For instance the study found that depending on what 
medicines one might be taking and the individuals enrollment 
plan, a person in one state may pay 10 percent of their annual 
income “for prescription drug coverage and premiums and co-
pays, while someone taking the same medicines in another state 
would spend 20 percent of their income.”315 The study also 
concluded that cost of living had no impact on disparate drug 
prices.316 In fact the researchers found that those in poorer parts 
of the country were generally paying more than others.317 
Matthew Davis, M.D. who led the study said “[t]his has 
implications for individuals’ ability to afford and keep taking 
their medicines, and for policy as the prescription drug benefit is 
BURLINGTON FREE PRESS, April 24, 2007. 
310 See Seay, supra note 4. 
311 Ceci Connolly, Drug Benefit Disparities Cited, WASH. POST, April 
19, 2005. 
312 Kara Gavin, Study: Senior Medicare drug costs vary widely among 
states, University of Michigan News Service, http://www.umich.edu/ 
~urecord/0607/Jan22_07/18.shtml. 
313 Study Finds “Tremendous” Disparity In Medicare Prescription Drug 
Prices, available at http://www.consumeraffairs.com/news04/2007/01/ 
medicare_rx_ prices.html. 
314 Id. 
315 Id. 
316 Id. 
317 Id. 
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evaluated and changes are considered.”318 Davis went on to 
state, “[n]o one doubts that the Part D benefit has helped many 
seniors by giving drug coverage to those who previously had 
none, but the level of variation among the lowest-cost plans is 
far greater than many seniors and policymakers probably 
anticipated.” 
The need for reform is clear considering drug manufacturers 
increased prices by 6.2% in 2006.319 General inflation was 
3.2%.320 The increase comes on the heels of a six year period 
where brand name drugs increased by 54%, compared to a 
general inflation rate of 20%.321 On the other hand the Medicare 
prescription drug benefit has been credited with increasing drug 
sales in the U.S. by 8.3% in 2006 by providing coverage to 
those were “previously uninsured or underinsured.”322 Thus, the 
drug benefit has led to improvements and some cost savings, but 
there is room for more. 
Reform has been on the minds of policy makers, as some in 
Congress are eager to pass legislation allowing Medicare to 
negotiate prices with drug companies.323 Presently, commercial 
insurers negotiate drug prices with pharmaceutical manufacturers 
and “set their own drug lists, premiums and co-pays.”324
A bill325 sponsored by Congressman John Dingell would 
change the current system and allow the HHS Secretary to 
318  Study Finds “Tremendous” Disparity In Medicare Prescription Drug 
Prices, available at http://www.consumeraffairs.com/news04/2007/01/ 
medicare_rx_ prices.html. 
319 AARP Rx Watchdog Report (AARP, Washington, DC), Mar. 2007. 
320 Id. 
321 Id. 
322 Theresa Agovino, Prescription-drug sales up 8.3% in U.S. for 2006, 
THE ARIZONA REPUBLIC, Mar. 10, 2007. 
323 Fischman, supra note 305. 
324 Study Finds “Tremendous” Disparity In Medicare Prescription Drug 
Prices, available at http://www.consumeraffairs.com/news04/2007/01/ 
medicare_rx_prices.html. 
325 Medicare Prescription Drug Price Negotiation Act of 2007, H.R. 4, 
110th Cong. (2007). This bill has passed the House of Representatives and is 
in Senate Committee. 
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negotiate lower drug prices with drug manufacturers.326 While 
critics contend that the bill is toothless because it doesn’t allow 
the Secretary the authority to limit the drugs covered by 
Medicare, a technique used by private insurers to get discounts, 
at least one proponent of the bill has argued that even if this is 
true at least the “secretive process of drug price setting will be 
exposed to public scrutiny.”327
D.  Potential Solutions to Reducing Drug Prices 
Other legislative efforts could be geared toward allowing 
generic drugs easier entry into the marketplace. Drug companies 
have been able to exploit a loophole in the current law that 
allows them to exclude generics from competing with their 
brand name drugs.328 Sources at the FDA have indicated that 
drug companies are misusing “citizen petitions”329 to prevent 
generic competition for longer than Congress intended.330 
Merely filing a petition initiates a review of the generic version 
of the drug by the FDA.331 The process often takes months, or 
even years to complete.332 FDA Chief Counsel Sheldon 
Bradshaw said these petitions, “appear designed not to raise 
timely concerns with respect to the legality or scientific 
soundness of approving a drug application, but rather to delay 
approval by compelling the agency to review arguments that 
could have been made months before.”333 One estimate indicates 
that a citizen petition, filed by the drug manufacturer Biovail 
326 Id. 
327 John Rother, Medicare Negotiating Authority Could Help Turn the 
Tide on High Drug Prices, AARP RX WATCHDOG REPORT, (AARP, 
Washington, DC) Jan.-Feb. 2007, at 4. 
328 Marc Kaufman, Petitions to FDA Sometimes Delay Generic Drugs, 
WASH. POST, July 3, 2006, at A1. 
329 Id. (noting that, “[R]equests for agency action that any individual, 
group or company can file.”). 
330 Id. 
331 Id. 
332 Id. 
333 Id. 
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Corp., delaying the introduction of a generic version of 
Wellbutrin to the marketplace is costing consumers $37 million 
per month.334
In an effort to facilitate the expansion of generic drugs, 
Senators Lott and Stabenow introduced legislation in the 109th 
Congress that would have allowed consumers earlier access to 
generic drugs and closed the “citizen petition” loophole.335 The 
legislation remained in Senate committee in the last Congress 
and has yet to be re-introduced in the 110th Congress. This 
issue has been the subject of reform efforts since the late 
1990s336 and thus it seems likely to once again be the subject of 
legislative debate. 
A bill337 currently before the Senate, sponsored by Senator 
Byron Dorgan and supported by members of both parties, would 
allow U.S. customers to order prescription drugs from nineteen 
countries around the world.338 The pharmaceutical industry 
immediately voiced its objection to the bill, with Tauzin 
reminding members of Congress of the serious threat 
counterfeiting poses and citing the Medicare prescription drug 
benefit as a source of reduced drug prices.339 Additionally, a 
2004 study by the Congressional Budget Office indicates that 
importation from foreign countries would save U.S. consumers 
only one percent over a ten year period and that a program that 
allowed importation only from Canada “would produce a 
334 Kaufman, supra, note 328. 
335 Lower Priced Drugs Act, S. 2300, 109th Cong. (2006). 
336 Kaufman, supra, note 328. ( citing that, “This is not the first time 
that the generic industry has complained about citizen petitions that it 
believed were unfairly blocking generic applications. The Clinton 
administration responded to those complaints in 1999 with a proposal that 
would have changed the way the FDA received and handled citizen petitions. 
PhRMA strongly opposed the rule, and the Bush administration withdrew it 
in 2003.”). 
337 Pharmaceutical Market Access and Drug Safety Act of 2007, S.242, 
100th Cong. (2007). 
338 Id. 
339 Matthew Perrone, Drug Imports Battle Heats Up Again, 
http://www.forbes.com/feeds/ap/2007/03/07/ap3495523.html. 
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negligible reduction in drug spending.”340
A potential complication to drug importation is the Canadian 
government’s threat to ban the bulk export of prescription 
drugs.341 In July, 2005 Canada’s health minister, Ujjal Dosanjh 
said “[w]e will enhance and systemize our drug-supply 
monitoring activity, and if necessary we will use export control 
to protect human health and our nation’s drug supply.” Later 
that same year Dosanjh told a Harvard Medical School audience, 
“[i]t is difficult for me to conceive of how a small country like 
Canada could meet the prescription drug needs of approximately 
280 million Americans without putting our own supply at 
risk.”342 He also stated that Canada “cannot be the drug store of 
the United States.”343 Despite Dosanjh’s explanation, Senator 
Dorgan blamed another culprit saying, “[t]his demonstrates the 
strength and the reach of the pharmaceutical industry,” noting 
that drug companies have tried to limit the amount of drugs they 
supply to Canada to “discourage the sale of those drugs to U.S. 
consumers.”344 In fact, seven pharmaceutical companies have 
reduced their supply of drugs to Canadian companies who sell to 
U.S. customers.345 Thus far, Canadians have not felt the effects 
of this reduction in medications thanks to stockpiling by 
Canadian pharmacists, but this is only a short term solution.346 
If Canada does place greater restrictions on the export of drugs 
to the United States it would be damaging to the state plans 
340 CONGRESSIONAL BUDGET OFFICE: ECONOMIC AND BUDGET ISSUE 
BRIEF, WOULD PRESCRIPTION DRUG IMPORTATION REDUCE U.S. DRUG 
SPENDING? (2004). 
341 Jeffrey Young, Canada may limit drug exports to U.S., The Hill, 
July 29, 2005, available at http://thehill.com/business—lobby/canada-may-
limit-drug-exports-to-u.s.-2005-07-29.html. 
342 Associated Press, Canada: Country cannot be U.S. drug store, USA 
Today, 2004, available at http://www.usatoday.com/news/health/2004-11-10-
canada-drugs_x.htm. 
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344 Young, supra note 341. 
345 See Seay, supra note 4. 
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described earlier.347 In fact, in response to the Canadian threat 
the state of Illinois began exploring opportunities to import 
pharmaceuticals from Belgium and France.348 Additionally, 
Rhode Island Secretary of State Matt Brown said reduced access 
to the Canadian market “would totally undermine our 
program.”349 Therefore, the reaction of the Canadian 
government to U.S. importation efforts will be an important 
factor in the success of state and federal importation programs. 
One avenue of compromise that has received less attention is 
the possibility of passing legislation that would prevent drug 
companies from advertising on television and radio. Since drug 
companies spend 27% of their revenue350 and approximately $4 
billion per year351 on direct to consumer advertising (“DTCA”) 
any reduction in those numbers would likely lead to a decrease 
in pharmaceutical costs352 to the U.S. consumer. Legislation of 
this kind is not unprecedented.353 In the early 1970’s Congress 
passed legislation banning the advertisement of cigarettes on 
television or radio.354 In order to satisfy first amendment 
safeguards protecting restrictions on commercial speech the 
government “must assert a substantial interest to be achieved by 
its restriction and employ a regulatory technique in proportion to 
that interest.”355 There is a strong argument that television 
advertisements for pharmaceutical drugs are harmful and that the 
only way to protect patient safety is to ban such advertisements. 
347 Young, supra, note 341. 
348 Canadian Drug Halt Looms, Illinois, Montana Seek New Sources, 
http://www.bloomberg.com/apps/news?pid=10000087&sid=aBIpIC2fQi7I&r
efer=top_world_news. 
349 Id. 
350 Khosravi, supra note 85, at 430. 
351 Robert Cohen, J&J Exec says pharma will fight ad ban, STAR 
LEDGER, Nov. 17, 2006. 
352 See Robert M. Crentor, Take drug ads off the air, USA TODAY, June 
12, 2005. 
353 See 15 U.S.C.S. § 1335 (1971). 
354 Id. 
355 Cent. Hudson Gas & Elec. Corp. v. Public Serv. Comm’n of New 
York, 447 U.S. 557, 564 (1980). 
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Direct to consumer advertising can result in the public desiring 
newer drugs that are not as effective as drugs that have been in 
the market much longer.356 When combined with the FDA’s less 
rigorous drug approval process and lack of follow up testing,357 
newly advertised drugs can have dangerous consequences. 
Perhaps the best example is the aforementioned heart attacks and 
deaths caused by Vioxx.358 One study on direct to consumer 
advertising found that “more advertising leads to more requests 
for advertised medicines, and more prescriptions. If DTCA 
opens a conversation between patients and physicians, that 
conversation is highly likely to end with a prescription, often 
despite physician ambivalence about treatment choice.”359 
Perhaps that is why the United States is one of only two 
countries that allows direct to consumer advertising.360
Moreover, as the tragic consequences of the Vioxx episode 
demonstrate, it is also likely that physicians will prescribe 
requested advertised drugs even if more effective treatments 
exist.361 In 2005, there was legislative action to limit the amount 
of television and radio advertising of prescription drugs, but 
those proposals did not make it out of House committee.362 
Neither of the previous proposals goes as far as banning 
television and radio advertisements of prescription drugs, but it 
seems clear that an effort to do so would not only increase 
patient safety but would also create more affordable drugs for 
U.S. consumers.363
356 Barbara Mintzes, Morris L. Barer, Richard L. Kravitz, Ken Bassett, 
Joel Lexchin, Arminee Kazanjian, Robert G. Evans, Richard Pan & Stephen 
A. Marion, How does direct-to-consumer advertising affect prescribing? A 
survey in primary care environments with and without legal DTCA, 169 
CANADIAN MEDICAL ASSOCIATION JOURNAL, 405, 406 (2003). 
357 See supra Section V.C. 
358 Id. 
359 Mintzes, supra note 356, at 406. 
360 Id. 
361 See Rita Rubin, Newest drugs not always the best, USA TODAY, Oct. 
18, 2006, at 9D. 
362 H.R. 1420, 109th Cong. (2005); H.R. 3950, 109th Cong. (2005). 
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CONCLUSION 
There is no doubt that soaring prescription drug prices must 
be remedied. However, that remedy should not require 
jeopardizing the safety of prescription drugs or opening our 
borders to products of unknown sources. The findings of the 
FDA, HHS Secretaries past and present, some state governments 
and others indicates that there are legitimate risks in 
implementing a full scale drug reimportation plan. Although 
there is optimism that the current political and economic 
landscape will result in drug reimportation being passed, the 
reality is that drug companies have gained desirable results for 
decades. Alternatives to drug reimportation exist and they should 
be thoroughly explored before we expose ourselves to the risks 
reimportation entails. 
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